Experimental Therapies: New treatments for hepatitis C including pre-clinical
development that have not yet been studied in humans, and various drugs that
are in phase I, II and III development to treat hepatitis C.
·
Experimental
o General
§
445. A Pilot Study to Assess
the Impact of Rosuvastatin Therapy on HCV RNA and lipid fractions in Chronic
Hepatitis C Patients. (updated, May 23)
§
M1794. PF-03491390, a pancaspase
inhibitor, reduces aminotransferases levels and is well tolerated in patients
with chronic hepatitis C (HCV). (updated,
May 23)
§
M1812. In Vivo Efficacy of a
Fully Human Monoclonal anti-E2 Immunoglobulin in Passive Immunoprophylaxis of
HCV Infection.
§
M1840. Trial of oral n-acetylcysteine
(NAC) to treat insulin resistance in chronic hepatitis C(HCV). (updated, May 21)
o Celgosivir
§
442.
Phase II Study of celgosivir in combination with
Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype-1
non-responder patients (updated, May 28)
o Consensus Interferon
·
M1877. Daily Consensus
Interferon-α (CIFN) and Weight-based Ribavirin (WBR) as First-Line Therapy
for HCV Patients with High Likelihood of Treatment Failure (HLTF): Interim
Analysis of a Cohort.
o HCV-796
§
364. Favorable Cross-Resistance
Profile of HCV-796 and SCH-503034 and Enhanced Anti-Replicon Activity Mediated
By Combination Treatment. (updated,
May 28)
§
440. Pharmacodynamic Analysis
of the Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796,
in Combination With Pegylated Interferon Alfa-2b in Treatment-Naïve Patients
With Chronic HCV (updated, May 28)
o Interferon Beta
§
M1803. Feasibility of induction
by twice-daily administration of interferon-beta prior to the standard
combination therapy using pegylated interferon-alpha-2b plus ribavirin.
o ITMN-191
§
M1816. Characterization of HCV NS3/4A
Protease Inhibition by ITMN-191 Reveals Picomolar Potency and Slow
Dissociation: Implications for the Use of ITMN-191 in Chronic HCV Treatment (updated,
May 24)
o Omega Interferon
§
M1798.
Phase 2 Study of Omega Interferon Alone or in
Combination with Ribavirin in Interferon-naïve Subjects with Genotype-1 Chronic
Hepatitis C (updated, May 23)
o R1626
o SCH-503034
o Taribavirin (Viramidine)
§
M1805. Pre-Dosing Taribavirin
Prior to Combination Therapy With Pegylated Interferon
Alfa-2b Versus Standard Combination Dosing: 24-Week Interim Results Examining
Safety and Viral Kinetics. (updated, May 23)
§
M1811.
Pharmacokinetic/Pharmacodynamic (PKPD) Modeling of Hemoglobin (Hgb) in a Phase
3 Study With Taribavirin and Ribavirin in
Therapy-Naïve HCV Patients. (updated, May 21)
o Telaprevir (VX-950)
§
443. Predicting HCV Treatment Duration
with an HCV Protease Inhibitor Co-administered with Peg-IFN/RBV by Modeling
both Wild-type Virus and Low Level Resistant Variant Dynamics.
o Valopicitabine (NM283)
§
M1796. Final Results from a Phase
IIA Pharmacokinetic Study of Valopicitabine (NM283) and Peg-IFNα-2b in
Patients with Genotype 1 Chronic Hepatitis C.